

Special Issue

Nanotechnology-Based Approaches for Chronic Diseases

Message from the Guest Editors

Chronic diseases like neurodegenerative diseases, cancers, diabetes, arthritis, cardiovascular diseases and so on are rapidly increasing worldwide. Despite this, the treatment for the chronic neuronal complications is still limited due to the difficulty for drugs to cross the blood–brain barrier, which has led researchers to search for novel medicines with a lower particle size. Similarly, other chronic diseases are also facing problems in the delivery of drug or other bioactive compounds to the target site. Nanotechnology-based medicines are currently in the pipeline for the effective delivery of those drugs with a lower particle size and the enhanced bioavailability of these drugs. The nanotechnology-based delivery of drug or bioactive compounds is an emerging trends in the protection, treatment or prevention of chronic diseases. Thus, this Special issue focuses on but is not limited to the following key sectors:

- Nanodelivery system development for chronic diseases
- Nanotechnologies used for drug development like micronization
- Nanotechnology-based molecular interactions
- Targeted nanomedicines
- Nanotoxicology
- Nanoimaging

Guest Editors

Dr. Palanivel Ganesan

Dr. Karthivashan Govindarajan

Prof. Dr. Dong-Kug Choi

Deadline for manuscript submissions

closed (31 October 2019)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/20456

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).